Reduction of the immunosuppressive action of chemotherapeutics in patients with mammary carcinoma by Azimexon.
Patients treated by aggressive cytostatic treatment exhibit marked deficiencies in cell-mediated immunity. Our investigations were performed in order to find out whether these immunosuppressive effects could be diminished by supportive treatment with the new synthetic immunomodulating compound BM 12.531, INN: AZIMEXONE. After inducing remission in ten patients with metastasizing breast cancer by a combination chemotherapy given for about one year, leucocytes, T- and B-lymphocytes and reactivity of peripheral lymphocytes to different mitogens were determined at weekly intervals before (8 X), during (8 X while on 100 mg i.v. weekly, then 4 X while on 400 mg i.v. weekly) and after (4 X) treatment with AZIMEXONE. Chemotherapy-induced immunosuppression could be markedly diminished during the administration of AZIMEXONE. A significant increase in the peripheral leucocyte count and mitogen-induced lymphocyte transformation could be achieved without any marked influence on the percentages of T- and B-cells. No severe side-effects of AZIMEXONE were observed.
D001388:Aziridines / Q000009:adverse effects / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D001943:Breast Neoplasms / Q000188:drug therapy*; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007958:Leukocyte Count; D008213:Lymphocyte Activation / Q000187:drug effects; D013601:T-Lymphocytes / Q000276:immunology
D001388:Aziridines; D001389:Azirines; C016866:azimexon